OBJECTIVE: To examine plasma microRNA-21 (miR-21) level in patients with non-small cell lung cancer (NSCLC) and its potential correlation with chemotherapeutic response. METHODS: 77 NSCLC patients and 36 age and sex-matched healthy controls were included. Plasma miR-21 concentration was examined using a quantitative real-time reverse transcription polymerase chain reaction assay (qRT-PCR). Potential correlation between plasma mir-21 concentrations with chemotherapeutic responses was analyzed in 35 patients with advanced NSCLC (stages IIIB and IV). RESULTS: Plasma miR-21 was significantly higher in NSCLC patients relative to the healthy controls (P<0.0001). As a biomarker, plasma mir-21 had a receiver operating characteristic (ROC) curve area of 0.729 with 61.04% sensitivity and 83.33% specificity. Chemotherapeutic response in the 35 patients with advanced NSCLC (stages IIIB and IV) included partial response (PR) (n=11), stable disease and progression disease (SD+PD) (n=24). The overall response rate (CR+PR) was 31.4%. Plasma miR-21 in patients who achieved PR was significantly lower than those who did not respond (SD+PD) (P=0.0487), and comparable to that of the healthy controls (P=0.2744). CONCLUSION: Plasma miR-21 is a good biomarker for NSCLC, and could be used to predict responses to chemotherapy.
OBJECTIVE: To examine plasma microRNA-21 (miR-21) level in patients with non-small cell lung cancer (NSCLC) and its potential correlation with chemotherapeutic response. METHODS: 77 NSCLCpatients and 36 age and sex-matched healthy controls were included. Plasma miR-21 concentration was examined using a quantitative real-time reverse transcription polymerase chain reaction assay (qRT-PCR). Potential correlation between plasma mir-21 concentrations with chemotherapeutic responses was analyzed in 35 patients with advanced NSCLC (stages IIIB and IV). RESULTS: Plasma miR-21 was significantly higher in NSCLCpatients relative to the healthy controls (P<0.0001). As a biomarker, plasma mir-21 had a receiver operating characteristic (ROC) curve area of 0.729 with 61.04% sensitivity and 83.33% specificity. Chemotherapeutic response in the 35 patients with advanced NSCLC (stages IIIB and IV) included partial response (PR) (n=11), stable disease and progression disease (SD+PD) (n=24). The overall response rate (CR+PR) was 31.4%. Plasma miR-21 in patients who achieved PR was significantly lower than those who did not respond (SD+PD) (P=0.0487), and comparable to that of the healthy controls (P=0.2744). CONCLUSION: Plasma miR-21 is a good biomarker for NSCLC, and could be used to predict responses to chemotherapy.
Authors: Krystian Jazdzewski; Elizabeth L Murray; Kaarle Franssila; Barbara Jarzab; Daniel R Schoenberg; Albert de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2008-05-12 Impact factor: 11.205
Authors: José Miguel García; Vanesa García; Cristina Peña; Gemma Domínguez; Javier Silva; Raquel Diaz; Pablo Espinosa; Maria Jesús Citores; Manuel Collado; Félix Bonilla Journal: RNA Date: 2008-05-02 Impact factor: 4.942
Authors: Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2008-07-28 Impact factor: 11.205
Authors: Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris Journal: JAMA Date: 2008-01-30 Impact factor: 56.272
Authors: Charles H Lawrie; Shira Gal; Heather M Dunlop; Beena Pushkaran; Amanda P Liggins; Karen Pulford; Alison H Banham; Francesco Pezzella; Jacqueline Boultwood; James S Wainscoat; Christian S R Hatton; Adrian L Harris Journal: Br J Haematol Date: 2008-03-03 Impact factor: 6.998
Authors: Melissa Piper Hunter; Noura Ismail; Xiaoli Zhang; Baltazar D Aguda; Eun Joo Lee; Lianbo Yu; Tao Xiao; Jeffrey Schafer; Mei-Ling Ting Lee; Thomas D Schmittgen; S Patrick Nana-Sinkam; David Jarjoura; Clay B Marsh Journal: PLoS One Date: 2008-11-11 Impact factor: 3.240
Authors: Yan Wang; Jian Gu; Jack A Roth; Michelle A T Hildebrandt; Scott M Lippman; Yuanqing Ye; John D Minna; Xifeng Wu Journal: Cancer Res Date: 2013-06-17 Impact factor: 12.701
Authors: Femke Simmer; Sabine Venderbosch; Jeroen R Dijkstra; Elisa M Vink-Börger; Claudius Faber; Leonie J Mekenkamp; Miriam Koopman; Anton F De Haan; Cornelis J Punt; Iris D Nagtegaal Journal: Oncotarget Date: 2015-09-08